Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
Timothée Bruel,Jérôme Hadjadj,Piet Maes,Delphine Planas,Aymeric Sève,Isabelle Staropoli,Florence Guivel-Benhassine,Françoise Porrot,William Bolland,Yann Nguyen,Marion Casadevall,Caroline Charre,Hélène Péré,David Veyer,Matthieu Prot,Artem Baidaliuk,Lize Cuypers,Cyril Planchais,Hugo Mouquet,Guy Baele,Luc Mouthon,Laurent Hocqueloux,Etienne Simon-Loriere,Emmanuel André,Benjamin Terrier,Thierry Prazuck,Olivier Schwartz +26 more
Reads0
Chats0
TLDR
In this article , the sensitivity of BA.1 and BA.2 to neutralization by nine therapeutic monoclonal antibodies (mAbs) was compared, and it was found that BA. 2 was sensitive to cilgavimab, partly inhibited by imdevimab and resistant to adintrevimab.Abstract:
The severe acute respiratory syndrome coronavirus 2 Omicron BA.1 sublineage has been supplanted in many countries by the BA.2 sublineage. BA.2 differs from BA.1 by about 21 mutations in its spike. In this study, we first compared the sensitivity of BA.1 and BA.2 to neutralization by nine therapeutic monoclonal antibodies (mAbs). In contrast to BA.1, BA.2 was sensitive to cilgavimab, partly inhibited by imdevimab and resistant to adintrevimab and sotrovimab. We then analyzed sera from 29 immunocompromised individuals up to 1 month after administration of Ronapreve (casirivimab and imdevimab) and/or Evusheld (cilgavimab and tixagevimab) antibody cocktails. All treated individuals displayed elevated antibody levels in their sera, which efficiently neutralized the Delta variant. Sera from Ronapreve recipients did not neutralize BA.1 and weakly inhibited BA.2. Neutralization of BA.1 and BA.2 was detected in 19 and 29 out of 29 Evusheld recipients, respectively. As compared to the Delta variant, neutralizing titers were more markedly decreased against BA.1 (344-fold) than BA.2 (nine-fold). We further report four breakthrough Omicron infections among the 29 individuals, indicating that antibody treatment did not fully prevent infection. Collectively, BA.1 and BA.2 exhibit noticeable differences in their sensitivity to therapeutic mAbs. Anti-Omicron neutralizing activity of Ronapreve and, to a lesser extent, that of Evusheld is reduced in patients’ sera. Therapeutic antibodies, and sera from immunocompromised individuals prophylactically treated with therapeutic antibodies, differ in neutralizing activity against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages, which could have implications for pre-exposure and post-exposure treatment. read more
Citations
More filters
Journal ArticleDOI
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Yunlong Cao,Ayijiang Yisimayi,F. Jian,Weiliang Song,T. Xiao,Lei Wang,Shuo Du,Qianqian Li,Xiao-song Chen,Yuanling Yu,Peng Wang,Zhiying Zhang,Pulan Liu,Ran An,Xiaohua Hao,Yao Wang,Jing Wang,Rui Feng,Haiyan Sun,Li-Jin Zhao,Wen Zhang,Dong Zhao,Jiang Zheng,Lingling Yu,Can Li,Na Zhang,Rui Wang,Xiaowei Niu,Siyuan Yang,Xuetao Song,Yangyang Chai,Ye Hu,Yansong Shi,Lin-Sheng Zheng,Zhiqiang Li,Qingqing Gu,Fei Shao,Weijin Huang,Ronghua Jin,Zhong-yang Shen,Youchun Wang,Xiangxi Wang,Junyu Xiao,Xiaoliang Sunney Xie +43 more
TL;DR: In this paper , the authors show that BA.4/BA.5 exhibit higher transmissibility than BA.2.1, BA.12.1 and BA.1.
Journal ArticleDOI
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Yunlong Cao,Ayijiang Yisimayi,F. Jian,Weiliang Song,T. Xiao,Lei Wang,Shuo Du,Jing Wang,Qianqian Li,Xiao-song Chen,Yuanling Yu,Peng Wang,Zhiying Zhang,Pulan Liu,Ran An,Xiaohua Hao,Yao Wang,Rui Feng,Haiyan Sun,Li-Jin Zhao,Wen Zhang,Dong Zhao,Jiang Zheng,Ling-li Yu,Can Li,Na Zhang,Rui Wang,Xiaowei Niu,Siyuan Yang,Xuetao Song,Yangyang Chai,Yeping Hu,Yansong Shi,Lin-Sheng Zheng,Zhiqiang Li,Qingqing Gu,Fei Shao,Weijin Huang,Ronghua Jin,Zhong-yang Shen,Youchun Wang,Xiangxi Wang,Junyu Xiao,Xiaoliang Sunney Xie +43 more
TL;DR: In this article , the authors show that BA.4/BA.5 exhibit higher transmissibility than BA.2.1, BA.12.1 and BA.1.
Journal ArticleDOI
Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
TL;DR: The theories that have been proposed on the evolution of Omicron including zoonotic spillage, infection in immunocompromised individuals and cryptic spread in the community without being diagnosed are examined.
Journal ArticleDOI
Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
letters-and-commentsDOI
Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
Emi Takashita,Seiya Yamayoshi,Viviana Simon,Harm van Bakel,Emilia Mia Sordillo,Andrew Pekosz,Shuetsu Fukushi,Tadaki Suzuki,Ken Maeda,Peter Halfmann,Yuko Sakai-Tagawa,Mutsumi Ito,Shinji Watanabe,Masaki Imai,Hideki Hasegawa,Yoshihiro Kawaoka +15 more
References
More filters
Journal ArticleDOI
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Dora Pinto,Young-Jun Park,Martina Beltramello,Alexandra C. Walls,M. Alejandra Tortorici,M. Alejandra Tortorici,Siro Bianchi,Stefano Jaconi,Katja Culap,Fabrizia Zatta,Anna De Marco,Alessia Peter,Barbara Guarino,Roberto Spreafico,Elisabetta Cameroni,James Brett Case,Rita E. Chen,Colin Havenar-Daughton,Gyorgy Snell,Amalio Telenti,Herbert W. Virgin,Antonio Lanzavecchia,Michael S. Diamond,Katja Fink,David Veesler,Davide Corti +25 more
TL;DR: Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Journal ArticleDOI
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Delphine Planas,David Veyer,Artem Baidaliuk,Isabelle Staropoli,Florence Guivel-Benhassine,Maaran Michael Rajah,Maaran Michael Rajah,Cyril Planchais,Françoise Porrot,Nicolas Robillard,Julien Puech,Matthieu Prot,Floriane Gallais,Pierre Gantner,Aurélie Velay,Julien Le Guen,Najiby Kassis-Chikhani,Dhiaeddine Edriss,Laurent Bélec,Aymeric Sève,Laura Courtellemont,Hélène Péré,Laurent Hocqueloux,Samira Fafi-Kremer,Thierry Prazuck,Hugo Mouquet,Timothée Bruel,Etienne Simon-Loriere,Félix A. Rey,Olivier Schwartz +29 more
TL;DR: In this paper, an infectious strain of the SARS-CoV-2 Delta variant was isolated from an individual with COVID-19 who had returned to France from India.
Journal ArticleDOI
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
Lihong Liu,Pengfei Wang,Manoj S. Nair,Jian Yu,Micah Rapp,Qian Wang,Yang Luo,Jasper Fuk-Woo Chan,Jasper Fuk-Woo Chan,Vincent Sahi,Amir Figueroa,Xinzheng V. Guo,Gabriele Cerutti,Jude Bimela,Jason Gorman,Tongqing Zhou,Zhiwei Chen,Zhiwei Chen,Kwok-Yung Yuen,Kwok-Yung Yuen,Peter D. Kwong,Peter D. Kwong,Joseph Sodroski,Michael T. Yin,Zizhang Sheng,Zizhang Sheng,Yaoxing Huang,Lawrence Shapiro,Lawrence Shapiro,David D. Ho +29 more
TL;DR: A diverse collection of potent neutralizing antibodies against the SARS-CoV-2 spike protein have been isolated from five patients with severe COVID-19 and high serum neutralization titres, suggesting both of these regions at the top of the viral spike are immunogenic.
Journal ArticleDOI
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Christopher O. Barnes,Claudia A. Jette,Morgan E. Abernathy,Kim Marie A. Dam,Shannon R. Esswein,Harry B. Gristick,Andrey G. Malyutin,Naima G. Sharaf,Kathryn E. Huey-Tubman,Yu E. Lee,Davide F. Robbiani,Davide F. Robbiani,Michel C. Nussenzweig,Michel C. Nussenzweig,Anthony P. West,Pamela J. Bjorkman +15 more
TL;DR: Eight new structures of distinct COVID-19 human neutralizing antibodies 5 in complex with the SARS-CoV-2 spike trimer or RBD are solved and rules for assigning current and future human RBD-targeting antibodies into classes, evaluating avidity effects and suggesting combinations for clinical use are provided.
Journal ArticleDOI
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Rui Shi,Chao Shan,Xiaomin Duan,Zhihai Chen,Peipei Liu,Jin-Wen Song,Tao Song,Tao Song,Xiaoshan Bi,Xiaoshan Bi,Chao Han,Lianao Wu,Lianao Wu,Ge Gao,Xue Hu,Ya-Nan Zhang,Zhou Tong,Weijin Huang,William J. Liu,Guizhen Wu,Bo Zhang,Lan Wang,Jianxun Qi,Hui Feng,Fu-Sheng Wang,Qihui Wang,George F. Gao,Zhiming Yuan,Jinghua Yan +28 more
TL;DR: Two monoclonal antibodies isolated from a patient with COVID-19 are shown to interfere with SARS-CoV-2–receptor binding, and one displays potent action against this virus in vitro and in a rhesus macaque model.
Related Papers (5)
The use of antipoliovirus monoclonal antibodies as an improved safety test for oral live poliomyelitis vaccine
The appearance of complement-requiring neutralizing antibodies by immunization and infection with herpes simplex virus.
A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques
Ronald R. Cobb,Joseph P. Nkolola,Pavlo Gilchuk,Abishek Chandrashekar,Robert V. House,Christopher G. Earnhart,Nicole M. Dorsey,Svetlana A. Hopkins,Doris M Snow,Rita E. Chen,Laura A. VanBlargan,Manuel Hechenblaickner,Brian Hoppe,Laura Collins,Milan T. Tomic,Genevieve H. Nonet,Kyal Hackett,James C. Slaughter,Michael S. Diamond,Robert H. Carnahan,Dan H. Barouch,James E. Crowe +21 more